# Progression of Atrophy and Phenotypic Variability in Autosomal Dominant Stargardt-like Macular Dystrophy due to *PROM1* mutation

Aaron Ricca, MD



Department of Ophthalmology and Visual Sciences

# **Financial disclosures**


None

## Summary

- Macular dystrophy that looks like Stargardt disease and AMD can be caused by a dominant mutation in PROM1 (p.R373C)
- Rates of atrophy progression are similar to those reported for ABCA4-related Stargardt disease and less than AMD
- Rates of atrophy vary based on early macular phenotype
  - Geographic atrophy > multi-focal GA > bulls-eye maculopathy

#### Autosomal dominant Stargardt-like macular dystrophy

- Rare, progressive retinal dystrophy, reduced acuity 2<sup>nd</sup> - 5<sup>th</sup> decade of life, macular atrophy and fundus flecks
- Known mutations:
  - ELOVL4 more common mutation
  - PROM1 mutation heterogeneity
- Goals
  - Describe clinical spectrum of disease
  - Quantify rate of progressive macular atrophy




Cibis et al. Archives of Ophth 1980. Stone et al. Archives of Ophth 1994. Michaelides et al. IOVS 2010.

### Methods

Single center, longitudinal retrospective case series


 Clinical data collected for patients with Arg373Cys (p.R373C) mutation in *PROM1*


 Areas of atrophy measured on Heidelberg Eye Explorer (version 6.3.2.0)




# **Demographics**

- 15 patients, 5 different families
- Age range 8 to 82
- 3 males, 12 females
- Average f/u 5.1 years (range 0-12)
- 3 types of macular atrophy
  - GA
  - Multi-focal GA
  - BEM








|                  |        |     | Initial Exam            |      | Final Exam               | Tune of street          | Vallou flacks | Peripheral pigment | Vascular    |
|------------------|--------|-----|-------------------------|------|--------------------------|-------------------------|---------------|--------------------|-------------|
|                  | Gender | Age | BCVA                    | Age  | BCVA                     | Type of atrophy         | Yellow flecks | clumping           | attenuation |
| Patient A:1,8    | Male   | 82  | 20/200 OD 20/200 OS     | Same | Same                     | Central GA              | No            | Yes                | No          |
| Patient A:II,15  | Female | 58  | 20/40 OD 20/80 OS       | 63   | 20/80-1+1 OD 20/100 OS   | Central GA              | Yes           | Yes                | Yes         |
| Patient A:III,25 | Male   | 49  | 20/25-1 OD 20/25-2 OS   | 50   | 20/30 OD 20/20-1 OS      | BEM                     | No            | No                 | No          |
| Patient A:III,38 | Female | 46  | 20/60+2 OD 20/320 OS    | 51   | 20/100-2 OD 10/300 OS    | Multi-focal GA          | No            | Yes                | Yes         |
| Patient A:II,20  | Male   | 25  | 20/30+2-2 OD 20/70 OS   | 37   | 20/1400 OD 20/1400 OS    | Multi-focal GA          | No            | Yes                | No          |
| Patient B:IV,12  | Female | 24  | 20/20 OD 20/125 OS      | 33   | 20/100-1 OD 20/100-1 OS  | BEM                     | No            | Yes                | No          |
| Patient B:IV,15  | Female | 31  | 20/15 OD 20/15 OS       | 34   | 20/20+2 OD 20/15-3 OS    | BEM                     | No            | No                 | No          |
| Patient B:IV,14  | Female | 26  | 20/60-2 OD 20/60-1 OS   | 36   | 20/100+2 OD 20/80+1-2 OS | BEM                     | No            | Yes                | No          |
| Patient B:III,6  | Female | 49  | 20/40-2 OD 20/20-1 OS   | 53   | 20/50+2 OD 20/25+2 OS    | BEM → multi-focal<br>GA | No            | Yes                | No          |
| Patient B:V,19   | Female | 9   | 20/20-2 OD 20/20- OS    | 11   | 20/20 OD 20/20+ OS       | BEM                     | No            | No                 | No          |
| Patient B:V,20   | Female | 8   | 20/25+ OU               | 10   | 20/20 OD 20/20 OS        | BEM                     | No            | No                 | No          |
| Patient C:III,16 | Female | 32  | 20/20-1 OD 20/25-1 OS   | Same | Same                     | BEM                     | No            | Yes                | No          |
| Patient C:II,8   | Female | 56  | 20/25 OD 20/20 OS       | 63   | 20/25-3 OD 20/20-2 OS    | BEM                     | Yes           | Yes                | No          |
| Patient 14       | Female | 48  | 20/40 OD 20/60+2 OS     | 55   | 20/125+2 OD 20/100-2 OS  | Multi-focal GA          | No            | Yes                | No          |
| Patient 15       | Female | 56  | 20/25-2+2 OD 20/25-2 OS | Same | Same                     | BEM                     | No            | Yes                | Yes         |

| Patient characteristics  |                        |                    |  |  |  |  |  |  |
|--|------------------------|--------------------|--|--|--|--|--|--|
|  | Percentage of patients | Number of patients |  |  |  |  |  |  |
| Gender   |                        |                    |  |  |  |  |  |  |
| Male   | 20%                    | 3                  |  |  |  |  |  |  |
| Female   | 80%                    | 12                 |  |  |  |  |  |  |
| Type of atrophy  |                        |                    |  |  |  |  |  |  |
| BEM  | 67%                    | 10                 |  |  |  |  |  |  |
| Multi-focal GA   | 20%                    | 3                  |  |  |  |  |  |  |
| GA   | 13%                    | 2                  |  |  |  |  |  |  |
| <b>Fundus findings</b>   |                        |                    |  |  |  |  |  |  |
| Yellow flecks  | 13%                    | 2                  |  |  |  |  |  |  |
| Pigment clumping   | 73%                    | 11                 |  |  |  |  |  |  |
| Vascular attenuation   | 20%                    | 3                  |  |  |  |  |  |  |
|  | Percentage of eyes     | Number of eyes     |  |  |  |  |  |  |
| Refractive error*  |                        |                    |  |  |  |  |  |  |
| Myopia   | 69%                    | 18                 |  |  |  |  |  |  |
| Hyperopia  | 23%                    | 6                  |  |  |  |  |  |  |
| Emmetropia   | 8%                     | 2                  |  |  |  |  |  |  |
| OCT findings*  |                        |                    |  |  |  |  |  |  |
| Hyporeflective spaces  | 8%                     | 2                  |  |  |  |  |  |  |
| *Refractive error and OCT analysis was not available for all eyes, |                        |                    |  |  |  |  |  |  |

percentages calculated based on total number of available eyes

| Rates of atrophy progression |                 |           |      |  |  |  |  |  |
|------------------------------|-----------------|-----------|------|--|--|--|--|--|
|                              | Rate of atrophy | Standard  |      |  |  |  |  |  |
|                              | (mm²/year)      | deviation |      |  |  |  |  |  |
| Type of atrophy              |                 |           |      |  |  |  |  |  |
| BEM                          | 0.23            |           | 0.14 |  |  |  |  |  |
| Multi-focal GA               | 0.53            |           | 0.31 |  |  |  |  |  |
| GA                           | 1.08            |           | 0.29 |  |  |  |  |  |
| All patients                 | 0.36            |           | 0.32 |  |  |  |  |  |



Patient A:II,15



Patient A:III,38




Patient A:III,25











#### Conclusions

- Macular dystrophy that looks like Stargardt disease and AMD can be caused by a dominant mutation in PROM1 (p.R373C)
- Rates of atrophy progression are similar to those reported for ABCA4-related Stargardt disease and less than AMD
- Rates of atrophy vary based on early macular phenotype
  - Geographic atrophy > multi-focal GA > bulls-eye maculopathy
- Early findings best seen on FAF and OCT and late findings variable



## **Thanks**

- Co-authors and mentors
  - -lan Han MD
  - Jeremy Hoffman
  - Edwin Stone, MD, PhD
  - Elliott Sohn, MD